A new peer-reviewed study suggests that semaglutide — the active ingredient in Ozempic and Wegovy — may do more than control blood sugar and reduce body weight. Published in the journal NPJ Aging, the research found early signals that semaglutide could slow biological aging at the DNA level, adding a potentially significant dimension to what GLP-1 drugs may offer patients.
What the Study Found
The research is a post hoc analysis of the SLIM LIVER trial (formally known as ACTG A5371, registered January 2, 2020 under NCT04216589). The 24-week, single-arm trial enrolled 41 people living with HIV (PWH) who also had metabolic dysfunction-associated steatotic liver disease (MASLD), a condition involving harmful fat buildup in the liver. Participants received semaglutide at a dose of 1.0 mg weekly.
Researchers used this dataset to examine epigenetic aging — biological changes to DNA that influence how quickly the body ages at a cellular level — and whether semaglutide treatment affected these markers. The study was already known to show that semaglutide improves metabolic health and reduces liver fat in this population; this new analysis probed deeper into whether those benefits extend to the biological aging process itself.
Why This Matters for GLP-1 Users
Most people taking semaglutide focus on its well-established benefits: weight loss, blood sugar regulation, and cardiovascular risk reduction. The suggestion that the drug may also influence epigenetic aging clocks — molecular markers tied to disease risk and longevity — opens a new avenue of interest. However, it is important to note that this is a pilot study with a small sample of 41 participants, all of whom were living with HIV. The findings are considered preliminary and should not be generalized broadly to all semaglutide users without further research in larger and more diverse populations.
Key takeaway: This is an early-stage, 41-person pilot study in a specific population (people with HIV and liver disease). While the epigenetic aging findings are intriguing, they are preliminary and not yet a reason to start or change semaglutide treatment on their own.
Important Limitations to Keep in Mind
- Small sample size: With only 41 participants, results may not apply widely.
- Specific population: All participants were living with HIV and had MASLD — a group with unique biological and treatment considerations.
- Single-arm trial: There was no placebo group, making it harder to isolate semaglutide's effect on aging markers from other variables.
- Post hoc analysis: The epigenetic aging question was not the original primary focus of the SLIM LIVER trial, adding another layer of caution in interpreting results.
What to Watch Next
Researchers will likely need larger, randomized controlled trials across broader populations — including people without HIV — to confirm whether semaglutide genuinely slows epigenetic aging and what that means clinically. The GLP-1 drug class is already under investigation for a wide range of conditions beyond diabetes and obesity, including kidney disease, heart failure, and addiction. Anti-aging effects, if confirmed, could further reshape how these medications are used and prescribed.
Frequently Asked Questions
As always, if you have questions about how findings like these apply to your own health or treatment plan, speak with your prescriber or a qualified healthcare provider before making any changes to your medication routine.
- PubMed, peer-reviewed publication in NPJ Aging, 'Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study,' date not specified in source material.